Interferon beta augments suppressor cell function in multiple sclerosis
- PMID: 2138445
- DOI: 10.1002/ana.410270219
Interferon beta augments suppressor cell function in multiple sclerosis
Abstract
Suppressor cell function has been previously reported to be decreased in patients with progressive multiple sclerosis (MS). The abnormality could not be corrected in vitro and was present even after patients were treated with immunosuppressive agents. We now report that interferon beta augments suppressor cell function in vitro in progressive MS. Nonspecific suppressor cell function as measured in a concanavalin A (Con A) suppressor assay was reduced in 24 MS patients (mean percent suppression, 19.6 +/- 2.2) when compared to 19 normal subjects (mean percent suppression, 35.0 +/- 3.3). The data are highly significant (p less than 0.001). When recombinant human interferon beta (10(3) units/ml) was added to lymphocyte cultures with Con A, suppressor activity improved significantly. The mean percent suppression improved from 19.6 +/- 2.2 to 37.8 +/- 2.6 in MS (p less than 0.001) and from 35.0 +/- 3.3 to 46.2 +/- 3.5 (p less than 0.025) in control subjects. This study shows that recombinant interferon beta improves suppressor function in humans, an effect that is particularly significant in progressive MS.
Similar articles
-
Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.Ann Neurol. 1992 Jan;31(1):103-6. doi: 10.1002/ana.410310119. Ann Neurol. 1992. PMID: 1371908
-
Activated suppressor cell function in severely disabled patients with multiple sclerosis.Ann Neurol. 1989 Feb;25(2):204-7. doi: 10.1002/ana.410250219. Ann Neurol. 1989. PMID: 2521994
-
Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis.J Immunol. 1986 Dec 1;137(11):3436-9. J Immunol. 1986. PMID: 2946761
-
Interferon beta in multiple sclerosis: is IL-12 suppression the key?Immunol Today. 2000 Jan;21(1):24-8. doi: 10.1016/s0167-5699(99)01541-8. Immunol Today. 2000. PMID: 10637555 Review. No abstract available.
-
Hypothesis: multiple sclerosis is a type I interferon deficiency syndrome.Proc Soc Exp Biol Med. 1998 Sep;218(4):278-83. doi: 10.3181/00379727-218-44295. Proc Soc Exp Biol Med. 1998. PMID: 9714071 Review. No abstract available.
Cited by
-
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.J Neurol. 2005 Sep;252 Suppl 3:iii28-iii33. doi: 10.1007/s00415-005-2014-2. J Neurol. 2005. PMID: 16170497 Review.
-
Mechanisms of action of interferon-beta in multiple sclerosis.Springer Semin Immunopathol. 1996;18(1):125-48. doi: 10.1007/BF00792613. Springer Semin Immunopathol. 1996. PMID: 8984676 Review. No abstract available.
-
Interferons in multiple sclerosis. A review of the evidence.Drugs. 1992 Dec;44(6):946-62. doi: 10.2165/00003495-199244060-00004. Drugs. 1992. PMID: 1282865 Review.
-
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.Biologics. 2009;3:369-76. Epub 2009 Jul 13. Biologics. 2009. PMID: 19707422 Free PMC article.
-
Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?CNS Drugs. 2004;18(15):1057-70. doi: 10.2165/00023210-200418150-00002. CNS Drugs. 2004. PMID: 15581378 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical